At left, FGF19.
By Emw - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=8767926
I recently wrote about the potential benefits of FGF19. However, in biology, many things are “double edged swords” and the same things that can promote useful growth in one context can, in another, promote cancer. Abstract:
Fibroblast growth factors (FGFs) and their cognate receptors, FGF receptors (FGFRs), play critical roles in a variety of normal developmental and physiological processes. Numerous reports support a role for deregulation of FGF-FGFR signaling, whether it is at the ligand and/or receptor level, in tumor development and progression. The FGF19-FGFR4 signaling axis has been implicated in the pathogenesis of several cancers, including hepatocellular carcinomas in mice and potentially in humans. This chapter focuses on recent progress in the understanding of the molecular mechanisms of FGF19 action and its potential involvement in cancer.
This is why various cutting edge treatments must always take into account potential side effects. Now, of course, there is a difference between normal and deregulated FGF signaling and it may be possible to use FGFs in therapy responsibly: the point is that all possibilities, both positive and negative, need to be considered and evaluated.
No comments:
Post a Comment